Difference between revisions of "Light-chain (AL) amyloidosis - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "_99|" to "_999|") |
m |
||
Line 1: | Line 1: | ||
+ | <span id="BackToTop"></span> | ||
+ | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | ||
+ | [[#top|Back to Top]] | ||
+ | </div> | ||
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? Please go to the [[Light-chain (AL) amyloidosis|main light-chain (AL) amyloidosis regimen page]] to find other regimens. | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? Please go to the [[Light-chain (AL) amyloidosis|main light-chain (AL) amyloidosis regimen page]] to find other regimens. | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
Line 21: | Line 25: | ||
| style="background-color:#1a9851" |Randomized (E-switch-ooc) | | style="background-color:#1a9851" |Randomized (E-switch-ooc) | ||
|[[#Melphalan_.26_Prednisone_.28MP.29|MP]] | |[[#Melphalan_.26_Prednisone_.28MP.29|MP]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
|[https://www.amjmed.com/article/0002-9343(87)90222-1 Cohen et al. 1987] | |[https://www.amjmed.com/article/0002-9343(87)90222-1 Cohen et al. 1987] | ||
Line 68: | Line 72: | ||
| style="background-color:#1a9851" |Randomized (E-switch-ooc) | | style="background-color:#1a9851" |Randomized (E-switch-ooc) | ||
|[[#Colchicine_monotherapy|Colchicine]] | |[[#Colchicine_monotherapy|Colchicine]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
| rowspan="2" |[https://doi.org/10.1056/NEJM199704243361702 Kyle et al. 1997] | | rowspan="2" |[https://doi.org/10.1056/NEJM199704243361702 Kyle et al. 1997] | ||
Line 77: | Line 81: | ||
|- | |- | ||
|2. [[#MP_.26_Colchicine_999|Melphalan, Prednisone, Colchicine]] | |2. [[#MP_.26_Colchicine_999|Melphalan, Prednisone, Colchicine]] | ||
− | | style="background-color:#ffffbf" | | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS |
|- | |- | ||
|} | |} |
Revision as of 13:18, 13 August 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main light-chain (AL) amyloidosis regimen page to find other regimens.
2 regimens on this page
2 variants on this page
|
First-line therapy (including transplant ineligible)
Colchicine monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kyle et al. 1985 | NR | Randomized (E-switch-ooc) | MP | Did not meet primary endpoint of OS |
Cohen et al. 1987 | 1976-1983 | Non-randomized | ||
Kyle et al. 1997 | 1982-1992 | Phase 3 (C) | 1. MP | Inferior OS |
2. Melphalan, Prednisone, Colchicine | Inferior OS |
Chemotherapy
References
- Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. link to original article PubMed
- Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H. Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med. 1987 Jun;82(6):1182-90. link to original article PubMed
- Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. link to original article PubMed
Melphalan & Prednisone (MP)
MP: Melphalan & Prednisone
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kyle et al. 1978 | NR | Randomized (E-esc) | Placebo | Longer time on treatment |
Kyle et al. 1985 | NR | Randomized (E-switch-ooc) | Colchicine | Did not meet primary endpoint of OS |
Kyle et al. 1997 | 1982-1992 | Phase 3 (C) | 1. Colchicine | Superior OS |
2. Melphalan, Prednisone, Colchicine | Did not meet primary endpoint of OS |
References
- Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. link to original article PubMed
- Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985 Dec;79(6):708-16. link to original article PubMed
- Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. link to original article PubMed